Reaction Details Report a problem with these data
Target
Malignant T-cell-amplified sequence 1
Ligand
BDBM345262
Substrate
n/a
Meas. Tech.
Assay 4: MCT1-Mediated Lactate Transport in BT20 Breast Cancer Cells
IC50
46000±n/a nM
Citation
 Parnell, KM; McCall, J MCT4 inhibitors for treating disease US Patent  US10202350 Publication Date 2/12/2019 
Target
Name:
Malignant T-cell-amplified sequence 1
Synonyms:
MCT-1 | MCT1 | MCTS1 | MCTS1_HUMAN | Multiple copies T-cell malignancies
Type:
Enzyme Catalytic Domain
Mol. Mass.:
20563.62
Organism:
Homo sapiens (human)
Description:
n/a
Residue:
181
Sequence:
MFKKFDEKENVSNCIQLKTSVIKGIKNQLIEQFPGIEPWLNQIMPKKDPVKIVRCHEHIEILTVNGELLFFRQREGPFYPTLRLLHKYPFILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAVDTIVAIMAEGKQHALCVGVMKMSAEDIEKVNKGIGIENIHYLNDGLWHMKTYK
  
Inhibitor
Name:
BDBM345262
Synonyms:
2-[[1-[(2-Chlorophenyl)methyl]-5-phenyl- pyrazol-3-yl]methoxy]-2-methyl- propanoic acid 1H NMR (DMSO-d6, 400 MHz) $#948; 1.56 (s, 6H), 4.58 (s, 2H), 5.41 (s, 2H), 6.56 (s, 1H), 6.75-6.78 (m, 1H), 7.20-7.30 (m, 4H), 7.32-7.43 (m, 4H). 1H NMR (CD3OD, 400 MHz) $#948; 1.54 (s, 6H), 4.589s, 2H), 5.40 (s, 2H), 6.55 (s, 1H), 6.68-6.74 (m, 1H), 7.20-7.42 (m, 8H). | US10202350, Example 8 | US10214492, Example 8 | US11292767, Example 8 | US11724989, Example 8
Type:
Small organic molecule
Emp. Form.:
C21H21ClN2O3
Mol. Mass.:
384.856
SMILES:
CC(C)(OCc1cc(-c2ccccc2)n(Cc2ccccc2Cl)n1)C(O)=O
Structure:
Search PDB for entries with ligand similarity: